Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) will hold a live webcast and conference call on November 12, 2020, at 8:30 a.m. ET to discuss updates and financial results for Q2 2020, which ended on September 30, 2020. Investors can access the call via Myovant’s investor relations website. The company is focused on innovative therapies for women's and men's health, with its lead product, relugolix, under regulatory review for uterine fibroids and advanced prostate cancer. A replay will be available on their site post-event.

Positive

• Relugolix under regulatory review in the U.S. and Europe for uterine fibroids.
• Relugolix monotherapy tablet is under regulatory review in the U.S. for advanced prostate cancer.
• Development of MVT-602, a treatment for female infertility, has completed Phase 2a study.

Negative

• None.

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2020, ended September 30, 2020. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on November 12, 2020.

Investors and the general public may access a live webcast of the call by visiting the investor relations page of Myovant’s website at investors.myovant.com. Institutional investors and analysts may also participate in the conference call by dialing 1-800-532-3746 in the U.S. or +1-470-495-9166 from outside the U.S.

A replay of the webcast, along with the earnings press release and presentation slides, will be archived on Myovant’s investor relations website.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our lead product candidate, relugolix, is a once-daily, oral GnRH receptor antagonist. Relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Relugolix monotherapy tablet (120 mg) is under regulatory review in the U.S. for men with advanced prostate cancer. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
media@myovant.com

FAQ

When is the Myovant Sciences Q2 2020 earnings call?

The Myovant Sciences Q2 2020 earnings call is scheduled for November 12, 2020, at 8:30 a.m. ET.

What is the focus of Myovant Sciences' product development?

Myovant Sciences focuses on innovative treatments for women's and men's health, particularly in areas like uterine fibroids and prostate cancer.

How can I access the Myovant Sciences earnings call?

You can access the earnings call by visiting Myovant’s investor relations website.

What is the ticker symbol for Myovant Sciences?

The ticker symbol for Myovant Sciences is MYOV.